drugset / Trial / NCT04042935
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
NaSequentialOpen-labelSupportive care
Summary
This is a phase I, single-center, non-randomized, 3+3 dose-escalation study of alpha lipoic acid given during chemotherapy-radiation in HNSCC patients with non-metastatic disease.
Timeline
- Start
- 2020-02-27
- Primary completion
- 2021-02-19
- Completion
- 2021-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | alpha-lipoic acid | Small molecule | 300 mg | Oral |
| Subject | alpha-lipoic acid | Small molecule | 600 mg | Oral |